Nuvilex, Inc. Pancreatic Cancer Therapy Offers Higher Survival Rate and Less Toxicity Than Competitors

Nuvilex, Inc. Pancreatic Cancer Therapy Offers Higher Survival Rate and Less 
Toxicity Than Competitors 
NEW YORK, NY -- (Marketwired) -- 05/02/13 --  Nuvilex, Inc. (OTCQB:
NVLX) has already produced impressive results from its two
independent Phase II clinical trials in patients with advanced,
inoperable pancreatic cancer. Two key results pulled from the data of
those trials, are that the median survival rate was higher than that
of the current gold standard for the disease and better than those of
other competitors' treatments when clinical trial reports are
examined. Furthermore, the overall side-effect profile (toxicity) was
much lower with Nuvilex's treatment than those of competitors'
treatments. 
Nuvilex's pancreatic cancer treatment uses the company's
"Cell-in-a-Box" or living cell encapsulation technology along with
the single anticancer drug ifosfamide. The encapsulated cells are
capable of converting the ifosfamide into its cancer-killing form.
Through two clinical trials, Nuvilex's treatment has performed
admirably with results that included a median survival time and
one-year survival rate that were doubled as compared to historical
data for Gemzar, the only drug to date approved by the FDA as a
single agent for the treatment of advanced, inoperable pancreatic
cancer.  
Digging deeper into those survival rate results, a finer point on the
data would be to simplify it down to real numbers. At the time
Nuvilex's clinical trials were conducted, Gemzar's historical data
gave patients a median survival time of 5.5 months; whereas,
Nuvilex's treatment during the two clinical trials resulted in a
median survival time of 11 months. 
In January of this year, NASDAQ's Celgene Corp. reported the results
for its treatment for advanced pancreatic cancer at the American
Society of Clinical Oncology's (ASCO) Gastrointestinal Cancers
Symposium in January. Celgene's treatment includes gemcitabine
(Gemzar) in combination with their drug Abraxane, a nanoparticle
albumin-bound formulation of paclitaxel (Taxol). 
Continue reading this article at www.stockhousegroup.com/features 
About Stock House Group 
Stock House Group is a full service Investment Relations firm
specializing in Awareness, Research, and Content Development. The
firm offers a platform
 that allows CEOs to tell their story through
the press with Feature Articles, Research Reports, and CEO
Interviews. At the same time, Stock House Group is building a library
of Research for Investors to use that allows them to get more
informed on small cap stocks. For more information visit Stock House
Group at www.stockhousegroup.com.  
Contact:
Stock House Group
www.stockhousegroup.com
info@stockhousegroup.com
646-397-4020 
 
 
Press spacebar to pause and continue. Press esc to stop.